Results 81 to 90 of about 43,876 (205)

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Metabolic and Volumetric Alterations in the Basal Ganglia and the Cerebellum in Dopa‐Responsive Dystonia in Symptomatic and Asymptomatic GCH1 Mutation Carriers

Movement Disorders, EarlyView.
ABSTRACT Background Dopa‐responsive dystonia is caused by pathogenic variants in the GCH1 gene. Although its clinical features and reduced penetrance are known, in vivo metabolic and structural alterations in symptomatic (sMC) and asymptomatic mutation carriers (aMC) remain poorly understood.
Jannik Prasuhn, Leon van Well, Marta M. Pokotylo, Feline Hamami, Joke‐Lina Aßmann, Katja Lohmann, Maximilian G. Ködderitzsch‐Mertins, Julia Henkel, Jan Uter, Alexander Münchau, Christine Klein, Anne Weissbach, Norbert Brüggemann   +12 more
wiley   +1 more source

Long‐Duration Response to Levodopa in the PPMI‐Cohort

Movement Disorders, EarlyView.
Abstract Background Treatment of Parkinson's disease (PD) with levodopa results in a sustained reduction of symptoms. Although the plasma half‐life of levodopa is short, it elicits a lasting effect, the long‐duration levodopa response (LDR). A decrease in LDR as PD progresses has been linked to motor complications, but long‐term data on the LDR and its
Nils Schnalke, Tim Feige, Tom Hähnel, Björn Falkenburger   +3 more
wiley   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Association of Preoperative Depression and Clinical Outcomes After Head and Neck Free Flap Reconstruction

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective Comorbid depression is a significant negative predictor of survival in patients with head and neck cancer (HNC). Prior studies have shown a prevalence of up to 40.1%; however, depression is often underdiagnosed in this patient population. Study Design Retrospective cohort. Setting Single‐institution database.
Sindhura Sridhar, Daniel P. Larson, Brooke B. Swain, Heezy Suh, Daniel R. S. Habib, Kelly Vittetoe, Donald Sengstack, Michael C. Topf, Melanie D. Hicks   +8 more
wiley   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

Unraveling the Physicochemical Landscape of Organoselenium Compounds in Nanocarrier Systems

The Chemical Record, EarlyView.
Main nanocarriers employed to enhance the bioavailability and transport of organoselenium compounds. The image illustrates the key interaction forces that stabilize these organoselenium species in solution, enabling their application in drug delivery systems, catalysis, photoelectronic devices, and sensing technologies. In recent years, publications on
Romelly Eugenia Rojas Ramírez, Tielle Moraes de Almeida, Daiani Canabarro Leite, Gilson Zeni   +3 more
wiley   +1 more source

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease

Patient Preference and Adherence, 2011
Bradley J RobottomDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, USAAbstract: Parkinson's disease (PD) is the second most common neurodegenerative disease and the most treatable.
Bradley J Robottom
doaj  

Dopamine: The Essential Bridge Mediating Obstructive Sleep Apnea and Hippocampus‐Dependent Learning and Memory Impairments

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Obstructive sleep apnea is a clinical syndrome that triggers a series of pathophysiologic changes, including disturbed sleep architecture, chronic intermittent hypoxia and hypercapnia, and ultimately severe cognitive dysfunction. The hippocampus plays a key role in various cognitive processes such as learning and memory.
Rui Fan, Tao Li, Yan Yan
wiley   +1 more source

Molecular aspects of monoamine oxidase B [PDF]

, 2016
Monoamine oxidases (MAO) influence the monoamine levels in brain by virtue of their role in neurotransmitter breakdown. MAO B is the predominant form in glial cells and in platelets.
Ramsay, Rona Ruth
core   +1 more source